bioRxiv Science⌕ Search

Biology subjects

Schmerer, P.

Publications and source records attributed to Schmerer, P..

3 recordsLinked to original sources

The RNA helicase eIF4A as a novel target in insect cells to combat arboviral infections

Arboviruses transmitted by mosquitoes cause major global health burdens, yet few vaccines or antivirals exist. Targeting host factors required for viral replication offers a promising approach. The DEAD-box RNA helicase eIF4A, a core component of the translation initiation complex eIF4F, unwinds structured 5' UTRs and is critical for many viral RNAs. We tested whether the natural products rocaglates and pateamines, potent eIF4A inhibitors in mammalian cells, also suppress arboviral replication and translation in insect vectors. Silvestrol strongly inhibited Rift Valley fever virus (RVFV) replication in human A549 cells without cytotoxicity, expanding the list of arboviruses dependent on eIF4A. Sequence analysis showed conservation of the rocaglate-binding motif between the arboviral vector Aedes aegypti and the fruit flies Anastrepha suspensa and Drosophila melanogaster. Dual-luciferase assays in insect cells of all three species confirmed silvestrol selectively inhibited translation from purine-rich reporters below cytotoxic thresholds. Purified eIF4A variants retained helicase activity, allowing direct testing of inhibitor interactions. Thermal shift assays demonstrated robust stabilization of eIF4A-RNA complexes by both compound classes in the wildtype proteins, with unexpected rocaglate sensitivity of the putatively insensitive Ae. aegypti H161L mutant, indicating a unique binding pocket geometry of the mosquito protein. Our results identify eIF4A as a conserved and druggable host factor in insects, highlighting its potential as a novel target for transmission-blocking antivirals and insect-specific inhibitors. Author SummaryNatural compounds from the classes of rocaglates and pateamines have shown their potential to inhibit tumor cell growth and to effectively suppress replication of different viruses, including Ebola, corona, picorna, and arboviruses by inhibiting translation initiation through blocking of one of the initiation actors, the helicase eIF4A. eIF4A is needed to unwind structured 5UTRs of selected mRNAs to allow binding of the 43S preinitiation complex. The compounds bind in a pocket of eIF4A, thereby clamping the RNA onto the eIF4A surface. Although eIF4A is highly conserved in eukaryotes not all eIF4A are sensitive to rocaglates. Mainly one key amino acid in the binding pocket determines sensitivity or insensitivity. In this study we expanded the list of arboviruses as potential targets of rocaglate-based drugs. Moreover, we approached the inhibition of arboviral infections from the vector side by studying the interaction between rocaglates and pateamines with eIF4A from the yellow fever mosquito Aedes aegypti, one of the most important arboviral vectors. Our study shows that also the mosquito eIF4A can be targeted by both compound classes. Moreover, our results reveal a unique architecture of the binding pocket that retains sensitivity even upon mutation of the key amino acid.

molecular biology↗

Low Density Lipoprotein Receptor-Related Protein 1 (LRP1) is a host factor for RNA viruses including SARS-CoV-2

Viruses with an RNA genome are often the cause of zoonotic infections. In order to identify novel pro-viral host cell factors, we screened a haploid insertion-mutagenized mouse embryonic cell library for clones that rendered them resistant to the zoonotic Rift Valley fever virus (RVFV; family Phleboviridae, order Bunyavirales). This screen returned the Low Density Lipoprotein Receptor-Related protein 1 (LRP1, or CD91) as top hit, a 600 kDa plasma membrane protein known to be involved in a wide variety of cell activities. Inactivation of LRP1 expression in human cells reduced RVFV RNA levels already at the attachment and entry stages of infection. Moreover, the role of LRP1 in promoting RVFV infection was dependent on physiological levels of cholesterol and on endocytosis. In the highly LRP1-positive human cell line HuH-7, LRP1 also promoted the early infection stages of Sandfly fever Sicilian virus (SFSV; family Phleboviridae, order Bunyavirales), La Crosse virus (LACV; family Peribunyaviridae, order Bunyavirales), had a minor effect on RNA levels during the late infection stages by vesicular stomatitis virus (VSV; family Rhabdoviridae, order Mononegavirales), whereas infection by Encephalomyocarditis virus (EMCV, family Picornaviridae) was entirely LRP1-independent. Moreover, siRNA experoments in human Calu-3 cells demonstrated that also SARS-CoV-2 infection benefitted from LRP1. Thus, we identified LRP1 as a host factor that supports infection by a spectrum of RNA viruses.

microbiology↗

Identification of SARS-CoV-2 induced pathways reveal drug repurposing strategies

The global outbreak of SARS-CoV-2 necessitates the rapid development of new therapies against COVID-19 infection. Here, we present the identification of 200 approved drugs, appropriate for repurposing against COVID-19. We constructed a SARS-CoV-2-induced protein (SIP) network, based on disease signatures defined by COVID-19 multi-omic datasets(Bojkova et al., 2020; Gordon et al., 2020), and cross-examined these pathways against approved drugs. This analysis identified 200 drugs predicted to target SARS-CoV-2-induced pathways, 40 of which are already in COVID-19 clinical trials(Clinicaltrials.gov, 2020) testifying to the validity of the approach. Using artificial neural network analysis we classified these 200 drugs into 9 distinct pathways, within two overarching mechanisms of action (MoAs): viral replication (130) and immune response (70). A subset of drugs implicated in viral replication were tested in cellular assays and two (proguanil and sulfasalazine) were shown to inhibit replication. This unbiased and validated analysis opens new avenues for the rapid repurposing of approved drugs into clinical trials.

pharmacology and toxicology↗